Related references
Note: Only part of the references are listed.Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses
S. B. Rizwan et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Multifunctional PLGA-Based Nanoparticles Encapsulating Simultaneously Hydrophilic Antigen and Hydrophobic Immunomodulator for Mucosal Immunization
Charlotte Primard et al.
MOLECULAR PHARMACEUTICS (2013)
Recent advances in the development of immunotherapeutic mAbs for cancer
Eva M. Riedmann
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
The mechanism of action of MF59 - An innately attractive adjuvant formulation
D. T. O'Hagan et al.
VACCINE (2012)
Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis
Puiying A. Mak et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
A Point Mutation in the Amino Terminus of TLR7 Abolishes Signaling without Affecting Ligand Binding
Carlo Iavarone et al.
JOURNAL OF IMMUNOLOGY (2011)
New adjuvants for human vaccines
M. Lamine Mbow et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine
Xilian Bai et al.
EXPERT REVIEW OF VACCINES (2010)
Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput Screening
Yue Guan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Pemphigus-like lesions induced by imiquimod
A. Bauza et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Fast Tracking the Vaccine Licensure Process to Control an Epidemic of Serogroup B Meningococcal Disease in New Zealand
Diana Lennon et al.
CLINICAL INFECTIOUS DISEASES (2009)
The path to a successful vaccine adjuvant - 'The long and winding road'
Derek T. O'Hagan et al.
DRUG DISCOVERY TODAY (2009)
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
Teresa R. Johnson et al.
VACCINE (2009)
A phase II dose-ranging study of topical resiquimod to treat actinic keratosis
R. -M. Szeimies et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species
Kristian S. Omland et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Clinical investigations of Toll-like receptor agonists
Thomas Meyer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation
Stanley L. Hem et al.
EXPERT REVIEW OF VACCINES (2007)
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
Paul J. Pockros et al.
JOURNAL OF HEPATOLOGY (2007)
A universal vaccine for serogroup B meningococcus
Marzia M. Giuliani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Data mining in the US using the vaccine adverse event reporting system
John Iskander et al.
DRUG SAFETY (2006)
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
RD Weeratna et al.
VACCINE (2005)
Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses
U Wille-Reece et al.
JOURNAL OF IMMUNOLOGY (2005)
Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model
M Otero et al.
VACCINE (2004)
Recent advances in the discovery and delivery of vaccine adjuvants
DT O'Hagan et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults
DN Sauder et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
M Jurk et al.
NATURE IMMUNOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing
M Pizza et al.
SCIENCE (2000)
Share Paper
